Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...
The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...
Vertex Pharmaceuticals won FDA approval for its non-opioid painkiller Journavx. Vertex stock jumped in late trading.
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...
The FDA has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.
U.S.-based Vertex Pharmaceuticals (VRTX) has secured approval from the FDA (Food and Drug Administration) for its long-awaited non-opioid ...
On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.
Vertex Pharmaceuticals Inc. (VRTX) has secured FDA approval for Suzetrigine, an oral, non-opioid, highly selective NaV1.8 pain signal ...
Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation ...
Vertex Pharmaceuticals on Thursday won approval from the Food and Drug Administration for a non-opioid pain drug, clearing ...